Vertex Pharma (VRTX) Misses Q3 EPS by 2c; Plans to Commence Two CF-Focused Phase 2s
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Stifel Positive on Vertex (VRTX) as Triple Combo Moves Forward; PT Trimmed to $108
October 26, 2016 9:22 AM EDTStifel analyst Adam Walsh trimmed his price target on Vertex (NASDAQ: VRTX) to $108.00 (from $109.00) but maintained a Buy rating as the triple combo moves forward.
Walsh commented, "At last, Vertex outlined the path forward for its triple combo regimens, removing an overhang on the stock as the competitive landscape heats up with Galapagos/Abbvie (not... More
Vertex (VRTX) PT Bumped to $88 at BMO Capital Following Results and Triple Combo Update
October 26, 2016 6:51 AM EDTBMO Capital analyst Do Kim bumped his price target on Vertex (NASDAQ: VRTX) to $88.00 (from $87.00) following results and the triple combo update but maintained a Market Perform rating.
Kim commented, " Vertex's 3Q16 was generally in line with expectations, as prior comments and revised... More
